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1. Introduction 
Bacterial Biosensors are engineered microorganisms that can be used to detect a variety of 
chemicals. These chemicals can include heavy metals, toxins, hormones, hormone-like drugs 
and environmental endocrine-disrupting pollutants. In general, bacterial biosensors are 
engineered to express a biosensing protein, which can selectively bind to a target chemical 
(usually referred to as a “ligand”).  When the target ligand is present, the biosensor protein 
produces an easily readable change in the cell behaviour. For example, the biosensing 
protein may produce a change in fluorescence or enzyme activity, or as shown in Fig. 1 & 2, 
may change the growth rate of the expressing cell when an appropriate ligand is present 
(Gillies et al, 2008; Skretas et al, 2007; Skretas & Wood, 2005a, 2005b, 2005c). 
 
 
Fig. 1. Growth dependent bacterial biosensor cell. A reporter protein gene is contained on a 
carrier plasmid, which is transformed into a microbial strain.  The expressed biosensor 
protein produces a ligand-sensitive growth phenotype.  In this case, the presence of the 
appropriate ligand for the biosensor protein increases the growth rate of the biosensor cells. 
The bacterial biosensors described in this chapter have been developed specifically for 
detecting and identifying chemicals that target human and animal nuclear hormone 
receptors (NHRs). As such, they can be used for identifying potentially valuable drugs for 
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treating a variety of cancers and metabolic disorders, or they can be used to detect and 
identify pathogenic environmental chemicals that act through various NHRs. In drug 
discovery, the link between chemicals binding to NHRs and various disease states is 
recognized across many different metazoans (Hu et al, 2008; Jofre & Karasov, 2008). 
 
 
(a) 
 
 
(b) 
Fig. 2. (a) Schematic representation of the NHR biosensor protein and related growth 
phenotypes (Gillies et al, 2008; Skretas et al, 2007; Skretas & Wood, 2005a). The activity of 
the TS reporter enzyme is dependent on the configuration of the allosteric sensor protein, 
which is modulated by the binding of an NHR ligand.  The activity of TS affects bacterial 
DNA synthesis and cellular metabolism (b). The resulting change in growth phenotype can 
be quantified by optical absorbance at 600 nm in liquid growth medium, allowing an 
indirect determination of the ligand’s agonistic or antagonistic behaviour. Abbreviations: ∆I-
SM (mini-intein splicing domain); MDB-maltose binding domain; TS-thymidylate synthase; 
dUMP- deoxyuridine monophosphate; dTMP- deoxythymidine monophosphate; FdUMP- 
5-fluoro-2’-deoxyuridine 5'-monophosphate; NADP- nicotinamide adenine dinucleotide 
phosphate; LBD-ligand binding domain of nuclear hormone receptor.  
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In humans, aberrant NHR binding of native and other hormone-like compounds is 
associated with a wide variety of disorders (Grycewicz & Cypryk, 2008), including 
dyslipidemia, hypogonadism, endometriosis, cancer, obesity and diabetes, as well as 
reproductive organ dysfunction and infertility (Feldman et al, 2008; Fessler, 2008; Malm et 
al, 2007; Mattsson & Olsson, 2007; Ohno, 2008; Tancevski et al, 2009; Tokumoto et al, 2007). 
Mitigation of these and other disorders, however, can also be accomplished through NHR 
manipulation, where hormone-like compounds can reverse or otherwise treat a wide variety 
of diseases. Similar pathogenic NHR binding effects can be seen in animals, where hormonal 
imbalances arise from environmental endocrine disrupting compounds (EDCs), such as 
pollutants and insecticides. These imbalances can lead to infertile egg production, tissue 
abnormalities, degraded gonadal structure, demasculization, altered species metamorphosis 
patterns and abnormally fast growth (Fernandez et al, 2007; Hu et al, 2008; Katsu et al, 2007; 
Rempel & Schlenk, 2008). For this reason, identification of EDCs and environmental 
screening for endocrine disrupting activity is a critical application as well. 
In humans, there are six major NHR groups, the best studied of which include the Estrogen 
Receptor (ER-like), Thyroid Hormone Receptor (TR-like) and Retinoid X Receptor (RXR-
like) (Doweyko, 2007). Inside the cells, these NHRs bind to DNA and various transcriptional 
co-activators and co-repressors to regulate the transcription of large numbers of genes in 
response to their hormone ligands.  This ability gives NHRs a tremendous impact on cell 
maturation, metabolism and homeostasis (Acosta-Martinez et al, 2007; Baxter & Webb, 2009; 
Brettes & Mathelin, 2008). 
A key element of the NHRs is that, in addition to their native hormones, they can bind to a 
wide variety of endocrine disruptors (EDs) and complex pharmaceuticals (Fig. 3).  Further, 
several subtypes can exist for a given NHR family (e.g., ERα or ERβ, and TRα or TRβ). 
Environmental pollutant EDs that target NHRs include BPA, PCBs, and dioxins, while 
endocrine active compounds in foods can include vitamins, phospholipids, phytoestrogens 
and fatty acids. Many pharmaceuticals have been developed to target NHRs, with the most 
important compounds typically exhibiting highly subtype-selective binding within an NHR 
group. Notable examples include the Selective Estrogen Receptor Modulators (SERMs; e.g. 
Raloxifene and Tamoxifen), and the Selective Thyroid Hormone Receptor Modulator 
(STRM; e.g. Eprotirome, currently in Phase II clinical trials) (Baxter et al, 2004; Leung et al, 
2007). The NHR proteins can also form homo- or hetero- dimers and tetramers within the 
NHR subclasses (e.g., ER-ER; ER-RXR), and can form various combinations of subtype 
homo- and heterodimers (e.g., ERα-ERβ dimer). These aspects of NHR action can greatly 
complicate their function in various cells and organs, leading to a wide variety of tissue-
specific effects in response to ligands of various classes. 
The similar structures and functions of the NHRs makes them a perfect fit for engineering 
biosensors, especially since they can be expressed well in bacteria or yeast cells. 
Additionally, the mechanism by which ligand binding triggers gene expression is well 
known, which has made NHRs and NHR LBDs highly tractable for drug discovery and 
environmental screening in high throughput systems. There are two basic classifications for 
compounds that bind to NHRs: agonists and antagonists. In general, agonist compounds 
tend to trigger hormone-related gene transcription, while antagonists tend to suppress 
transcription.  The exact response of a cell to a given endocrine active compound, however, 
depends on a variety of factors, which include the presence of various co-activators and co-
repressors and aspects of the metabolic state of the cell.  At the molecular level, the primary 
determinant for the differential response of the NHR to these two types of compounds is the 
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Fig. 3. Selected structures of compounds binding to NHRs. Thyroid receptor ligands include 
the compounds T3 (a natural TR agonist), TRIAC (a natural TR agonist), KB-141 (a synthetic 
TRβ-selective agonist) and GC-1 (a synthetic TRβ-selective agonist), while estrogen receptors 
bind tamoxifen (a subtype-selective ER modulator), raloxifene (a subtype-selective ER 
modulator), benzophenone-2 (an ER agonist found in many cosmetics and perfumes), 
GW7604 (a synthetic selective ER downregulator), EM652 (a synthetic selective ER 
downregulator), E2 (17-β-estradiol – the native ER ligand), BPA (an ER agonist and 
suspected ER-disruptor found in many consumer plastics), and DES (an ER agonist, 
formerly available small-molecule therapeutic which has been linked to cervical cancer). 
repositioning of a conserved helix, generally known as helix-12 (Fig. 4a), upon ligand 
binding (Gulla & Budil, 2007; Shiau et al, 2002). When the bound ligand is an agonist, helix-
12 tends to shift towards the NHR binding pocket, creating a charged area on the protein 
surface. This surface is then occupied by a co-activator, which results in initiation of 
transcription (MacGregor & Jordan, 1998; Schapira et al, 2000; Shiau et al, 1998). Antagonists 
are commonly equipped with bulky functional side group(s), causing helix-12 to rotate 
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away from the binding pocket, which typically results in suppression of transcription (Fig. 
4a; (Koehler et al, 2005)). 
 
 
(a) 
 
(b) 
Fig. 4. (a) Comparison of ER ligand binding domain structures, with a focus on helix-12 
repositioning in response to agonist binding (left; ERα bound to genistein, PDB ID: 1X7R) or 
antagonist (right; ERβ bound to 4-hydroxytamoxifen, or Nolvadex®, a common drug used in 
treatment for breast cancer patients, PDB ID: 3ERT). The solvent accessible surface around 4-
hydroxytamoxifen (structure shown in Fig. 3) is underlined in yellow on the right side of the 
compound. Genistein is inside of the active pocket, hidden behind the α-helixes. Upon 
antagonist binding to ER, helix-12 rotates away from the binding pocket due to the 
antagonist’s extended functional group.  This results in a change of the protein surface, 
making it inaccessible to co-activators. (b) Schematic representation of the NHR domains A 
through F (Hewitt & Korach, 2002; Norris et al, 1997). Abbreviations: AF-1 = Activation 
Function-1; AF-2a = Activation Function-2a; AF2 = Activation Function-2; DBD = DNA 
Binding Domain. 
2. Engineered allosteric bacterial biosensor 
In any screening process, the success of finding unique and active compounds depends 
greatly on the sensitivity of the method. A large diversity of available target proteins for 
screening is also essential, especially when searching for subtype-selective agonistic and 
antagonistic behaviours. Additionally, assay limitations must also be considered, such as the 
impacts of solvents used for delivering the test compounds, as well as growth media or 
temperature.  These aspects of the assay can greatly affect the numbers of false positive and 
false negative results, as well as the reproducibility and robustness of the assay.  Finally, for 
high throughput applications in large library drug screening, the assay must be simple, 
economical, and amenable to full or partial automation.  
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To generate bacterial biosensors for detecting hormones and hormone-like compounds, we 
have engineered the ligand-binding domains of various NHR proteins into an allosteric 
biosensor protein scaffold. The biosensor scaffold is composed of four protein domains, 
including a maltose binding domain, an intein stabilization domain, an NHR ligand-binding 
domain (LBD), and a thymidylate synthase (TS) reporter enzyme (Fig. 2). This scaffold is 
designed to link ligand binding by the NHR LBD to the activity of the fused TS reporter 
protein. Thymidylate synthase is a critical enzyme involved in bacterial DNA synthesis, which 
produces a strong growth phenotype on thymineless medium based on its activity. 
Specifically, the TS protein is part of bacterial folate metabolism, where it consumes a single 
methylene tetrahydrofolate molecule as it converts a single molecule of dUMP to dTMP. The 
dTMP is then used for DNA synthesis, which is required for cell growth. In practice, the 
chimeric sensor protein undergoes a structural change when an appropriate ligand is bound to 
the LBD, which alters the activity of the fused TS domain, and leads to a change in growth rate 
of the expressing bacterial cell (Fig. 2). The involvement of TS in the folate cycle allows both 
positive and negative selections for TS activity.  Further, the stringency of the selection can be 
tuned by modulating the incubation temperature and concentrations of the antibiotic 
trimethoprim (Belfort & Pedersen-Lane, 1984; Gillies et al, 2008; Skretas et al, 2007; Skretas & 
Wood, 2005a). Although there are some differences between species, NHRs share similar 
domain structures and sequences within the subgroups, which have allowed new NHR 
biosensors to be generated using the same basic sensor protein scaffold. The biosensing 
microbial strains expressing these proteins are referred to as “Bacterial Biosensors”.  
The NHR bacterial biosensors can be used to screen uncharacterized compounds for their 
effects on a variety of NHR targets.  In particular, this method can be used for the detection 
and differentiation of agonistic and antagonistic compounds, and can be used to determine 
the half-maximal effective concentrations (EC50 and IC50 values) for a given compound 
(Skretas et al, 2007; Skretas & Wood, 2005a). Additionally, these bacterial biosensors can 
detect NHR subtype selectivity of a given compound, as well as species selectivity when 
used with animal-based bacterial biosensors (Gierach et al, 2011).  In this case, the simple 
incorporation of an animal NHR ligand-binding domain generates a sensor for detecting 
ligands against that species. 
The recognition of agonistic or antagonistic behaviour is directly correlated with TS activity 
of the sensor, expressed as an increase or decrease of cell growth on selective growth 
medium (Skretas & Wood, 2005a). In this selection system, TS activity closely depends on 
the conformation of the LBD-ligand complex. Reduced activity of the TS reporter enzyme, 
which is observed in the absence of ligands, or with non-binding or antagonistic ligands, 
results in lower bacterial growth. High TS activity is elicited by agonist binding and can be 
detected by observing the rate of increase in culture optical density at 600 nm (OD600) over 
time. Importantly, the temperature plays an important role in the sensitivity of biosensors, 
and is related to the stability of TS and the cellular demand for dTMP. Therefore, bacterial 
cell growth is typically carried out in 96-well plates, incubated at precisely 34°C in a 
controlled humidity air shaker at 150 rpm (Gawrys et al, 2009; Gierach et al, 2011).  
Key features of the bacterial biosensors 
1. Each biosensor protein contains: Maltose Binding Protein-Intein-T4 Thymidylate 
Synthase Enzyme, with the NHR LBD inserted into the intein domain.  
2. The activity of the fused TS enzyme is modulated by the amount and potency of the 
NHR ligand present.  
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3. TS activity can be detected qualitatively by colony formation on selective agar medium, 
or both qualitatively and quantitatively by observing changes in liquid growth medium 
optical density at 600 nm wavelength over time.  
4. The LBD domain of one biosensor protein can be easily replaced with an alternate LBD, 
which has allowed the construction of functional biosensors for human ERα, ERβ, TRα, 
TRβ, PPARγ, fish (sole) ERβ and porcine (domestic pig) ERβ.  
5. The assay method is non-radioactive, and has been developed for high throughput 
screening (HTS). 
6. This method can detect strong ligands at low nM concentrations. 
7. Weakly bound ligands, such as BPA and Tamoxifen for the human estrogen receptor, 
can be detected at low µM concentrations. 
8. Three steps are required to complete a single set of assays: (a) overnight growth of fresh 
cells in non-selective LB medium; (b) dilution of the cells into a selective thymineless 
medium (–THY medium) and addition of the diluted test compounds and controls (this 
is done robotically in the HTS format); and (c) growth of cultures for 10 to 20 hours at 
34°C, 150 rpm agitation and controlled humidity. 
9. The limitations of the method are: the biosensor is sensitive to the presence of 
detergents, high levels of alcohols, solvents, and lipids (or any generally cytotoxic 
condition). Therefore, the final solvent concentration used in the assay should not 
exceed 1% DMSO or ethanol (test compound vehicle). 
2.1 Construction of the bacterial biosensor strain 
Vector and chimeric proteins 
The biosensor protein is expressed from the pMal-c2 plasmid (New England Biolabs, 
Beverly, MA), where the plasmid backbone encodes the maltose binding protein (MBD) 
under control of the Ptac promoter.  The biosensor gene is constructed through the 
following steps (Fig. 5): (1) the ∆I-SM gene, derived from the full-length Mycobacterium 
tuberculosis RecA intein (Wood et al, 1999), is fused to the C-terminus of the MBD; (2) the 
bacteriophage T4 td gene, encoding T4 TS reporter enzyme, is fused to the C-terminus of the 
∆I-SM gene; (3) the native intein splicing activity is suppressed by mutation of the N- and C-
terminal amino acids of the intein to alanine; (4) the NHR LBD is inserted into the ∆I mini-
intein gene at the location where the original intein endonuclease domain was deleted; and 
(5) the Ptac promoter sequence is mutated to slightly increase basal expression of the overall 
fusion protein (Skretas & Wood, 2005b). The resulting plasmid names have the general form 
pMIT::[NHR], where pMIT stands for plasmid MBD-∆I intein-TS reporter scaffold, and 
[NHR] is the inserted LBD (Fig. 5). The constructed sensor plasmids are then transformed 
into the E. coli TS knockout strain D1210∆thyA::KanR [F-∆(gpt-proA)62 leuB6 supE44 ara-14 
galK2 lacY1 ∆(mcrC-mrr) rpsL20 (Strr) xyl-5 mtl-1 recA13 lacIq] (Skretas et al, 2007). 
A key component of the biosensor protein is the split ∆I-SM mini-intein domain, which is 
thought to increase the stability of the overall fusion and transduce binding information to 
the TS enzyme. Mutations at the N-terminus of the mini-intein (Cys→Ala) suppresses intein 
splicing, while the MBD was added to assure the solubility and increase the activity of the 
chimeric protein. Insertion of the NHR LBD is commonly accomplished by utilizing unique 
AgeI and XhoI restriction sites within the intein, which flank the intein-NHR insertion site 
(Skretas & Wood, 2005b). The constructed biosensors include two different mini-inteins for 
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LBD insertion: 110∆383 and 96∆400 (Wood et al, 1999). The 110∆383 mini-intein was used 
more often, and includes the pMIT::ERβ*(h), pMIT::ERβ*(s), pMIT::ERβ*(p), pMIT::TRβ*(h) 
and pMIT::TRα*(h) biosensors, whereas the 96∆400 intein was used for the pMIT::ERα*(h) 
fusion (Gierach et al, 2011). The specific mechanism of the biosensor action in bacterial cells 
is currently under investigation. 
 
 
Fig. 5. Schematic representation of the plasmid vector pMal-c2 (top), which contains the 
MBD, intein, NHR LBD and TS genes.  The swappable NHR LBD gene is inserted between 
the N- and C-terminal fragments of the intein. Several constructed biosensor protein fusion 
genes are also shown (bottom). In these diagrams, Ptac = Ptac promoter for controlling 
biosensor protein expression; MBD = Maltose Binding Domain; N-Mtu = N-terminal 
segment (typically amino acids 1-110) of the ∆I-SM mini-intein; ERα, ERβ, TRα, TRβ = 
Estrogen Receptors alpha and beta, Thyroid Receptors alpha and beta, respectively, where 
(h) = human, (p) = porcine and (s) = sole; C-Mtu = C-terminal segment of the ∆I-SM mini-
intein; TS = Thymidylate Synthase reporter enzyme.  Plasmid names are shown on the right 
for each of the biosensor genes, where pMIT stands for plasmid MBD-∆I-TS and the :: 
symbol indicates insertion of the indicated LBD. 
2.2 Usage of the NHR bacterial biosensors 
2.2.1 The High Throughput Screening (HTS) 
The application of bacterial biosensors in a 96-well plate HTS format (Fig. 6) is based on an 
earlier protocol that employed glass culture tubes. The original glass culture tube method 
was very labor-intensive, and the number of samples and concentrations was limited by 
incubator space.  Most importantly, large quantities of growth medium and ligands were 
www.intechopen.com
Engineered Nuclear Hormone Receptor-Biosensors  
for Environmental Monitoring and Early Drug Discovery 
 
509 
needed for each experiment. The HTS method in 96-well plates is approximately 100 times 
more sensitive, and the cells, growth medium and ligands are dispensed by a robotic liquid 
handler (Biomek 2000, Beckman-Coulter), which assures greater mixing quality and 
repeatability. 
2.2.2 Agonism and antagonism detection by biosensors 
There are three major tests resulting in detection of ligand agonism and antagonism, as well 
as toxicity of the test compounds for bacterial cells (see Table 1).  
Compounds that stimulate the growth of cells in thymineless medium (-THY) are generally 
considered to be agonists, while antagonists can have no effect, or in some cases can 
decrease the growth of cells in –THY medium. Using estrogen receptor as an example, 
antagonist tests use competitive biosensor binding with estradiol (-THY+E2 assay), where 
antagonist lowers TS activity relative to E2 alone. However, in the TTM and TTM+E2 assays 
the phenotypes are reversed, and low TS activity upon antagonist binding rescues cells.  
This reversal is very helpful in confirming LBD-specific effects, as opposed to more general 
metabolic effects. Toxicity can be determined by adding an uncharacterized compound to 
cells growing in non-selective medium (+THY), where cells grow freely in the presence of 
agonists or antagonists, but toxicity results in a loss of growth. 
 
 
Fig. 6. Schematic representation of the intein-based biosensor method.   
2.2.3 Sub-type receptor selectivity 
The ligand binding domains of receptor subtypes are highly conserved (see Fig. 4), which 
allows multiple receptor subtypes to be used for biosensor generation. Differential binding 
to one biosensor subtype or another allows a quick determination of subtype selectivity for a 
given compound. In previous studies, we were able to confirm the subtype-selectivity of 
compounds bound to the estrogen receptors. Among them propylpyrazole triol (PPT) and 
methyl piperidinopyrazole (MPP) were found ERα selective, whereas DPN, Genistein and 
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Daidzein were ERβ selective.  The Relative Binding Affinities (the EC50 ratio between ERα 
and ERβ) of those compounds were in correlation with the literature; PPT (593), MPP (220), 
DPN (0.01), Genistein (0.002) and Daidzein (0.2) (Skretas & Wood, 2005b). Additionally, the 
TR biosensors were able to detect Triac, GC-1 and KB-141 TRβ selectivity (unpublished 
results), which are also in agreement with reported results (Bleicher et al, 2008; Grover et al, 
2005; Koury et al, 2009; Li et al, 2006; Marimuthu et al, 2002; Martinez et al, 2009; Scanlan, 
2008; Wagner et al, 2001).   
 
  -THY -THY+E2 TTM TTM+E2 +THY 
  34°C 34°C 37°C 37°C 37°C 
High TS 
Activity 
AGONISM + + - - + 
Low TS 
Activity 
ANTAGONISM - - + + + 
Low TS 
Activity 
TOXICITY n/a n/a n/a n/a - 
Table 1. Summary of the NHR bacterial biosensor assays and their conditions, including 
temperatures and growth medium additives for optimizing results (Skretas et al, 2007). The 
+/- signs indicate cell growth below or above the baseline OD600 value obtained for cells in 
the presence of solvent only (which is constant throughout the sample and not higher than 
1%). Abbreviations: TTM: -THY medium with 50µg/mL Thymine and 10µg/mL 
Trimethoprim;  +THY: -THY medium with 50µg/mL Thymine; E2 is 17-β-estradiol, typically 
at 0.1 to 10 µM depending on the test strain. 
2.2.4 Effect of compounds across different species 
We also confirmed in our studies that the effects of tested compounds varied across 
different species, such as sole (Solea solea) and human (Gierach et al, 2011). As expected, 
compounds expressed similar effects when bound to pig and human ERβs, but in some 
cases diverged for sole and human or pig. The fact that the biosensors are able to quantify 
differential effects across species can allow rapid screening of ED pollutants using consistent 
assay protocols, which will eliminate important barriers to comparing these types of data in 
the current literature. This creates great opportunities for understanding crosstalk of 
receptors in a wide range of species, and allows the selectivity of ligands across receptors 
and species to be explored. 
2.2.5 Synergism and competition of natural hormones, pharmaceuticals and EDCs 
There is a great concern that mixtures of EDCs could have stronger and more devastating 
effects than single compounds on health and environment. Since there is no limitation as to 
how many ligands can be tested simultaneously, the biosensor could detect synergistic 
effects acting through the NHR LBD as well. 
3. Bacterial biosensors in drug discovery 
The process of delivering new pharmaceuticals to the market takes approximately 10-15 
years and only one compound in 10,000 has a chance to be approved by the U.S. FDA. The 
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development cost per drug can reach $800 million on average (Brower, 2002). For these 
reasons, there is an urgency to discover new compounds that are more selective and have 
fewer side effects. Early stage discovery and pre-clinical research may take 6-7 years alone. 
  
 
Fig. 7. The process of designing a bacterial biosensor and its utilization. First, the sequence 
of the plasmid is constructed computationally. The template (e.g., pMIT::ERα) stays intact, 
and the insert (N-terminal intein-NHR LBD-C-terminal intein) is swapped to create a new 
biosensor with a different LBD. Next, the plasmid is transformed into a bacterial cell, which 
allows the encoded gene to be transcribed and translated into the active biosensor protein. 
In the presence of an agonist, the activity level of the TS reporter enzyme domain is 
increased, leading to an increase in cellular growth rate (see the graph above). However, 
when antagonists are present the activity of the TS is low, which allows a distinction 
between these two types of the compounds. Cell growth can be quantified by OD600 
measurements. The 3D structures of NHR LBDs proteins (such as the ER LBD shown above) 
can be found in the RCSB Protein Data Bank (PDB). 
Therefore, the development of new methods to rapidly screen millions of ligands against 
new targets is essential and ongoing. The identification of ligands that bind to estrogen 
receptor(s) began with the development of treatments for patients with hormonal 
dysfunctions, cancers, and sexually transmitted bacterial infections. Several early 
pharmaceuticals, such as diethylstilbestrol (DES, a nonsteroidal estrogen synthesized just 
before World War II by Leon Golberg), failed due to their high toxicity and disastrous side 
effects, such as breast cancer and vaginal adenocarcinoma in second-generation girls (Birch, 
1992; Jordan et al, 2008). The first human ER was discovered in 1966 by Jensen and Gorski, 
and it took an additional 30 years until the first mammalian ERβ sequence was cloned 
(Fannon et al, 2001). Interestingly, the compound tamoxifen, as well as second-generation 
benzothiophene derivative selective estrogen receptor modulators (SERMs) (e.g., raloxifene, 
known as Evista® (Pritchard, 2001; Wilkinson et al, 1982)), show unique selective action in 
targeted tissues. In some tissues SERMs act as an estrogen, and therefore their action is 
described as agonistic, but in others they block the effect of estrogen and behave as 
antagonists. In many cases, the mechanism of SERM action is not fully understood, and 
research is ongoing on the roles of the co-regulators, ligands, and cross-signaling proteins 
that mediate ER expression levels across the human body. For example, it was determined 
that ERβ is dominant in the gastrointestinal tract, whereas ERα dominates in liver. Both of 
these receptors are expressed in breast, bone and brain tissue, but in different ratios, 
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allowing direct targeting of specific organs (Gustafsson, 1999). During the last 10 years, the 
number of targeted drug-like compounds produced in industry and academia has increased 
dramatically. These compounds have been developed as fertility drugs, as well as breast 
cancer, prostate cancer and osteoporosis therapeutics. Among them are Toremifene 
(Fareston® by Shire laboratories), lasofoxifene, trioxifene, droloxifene, clomifene (Clomid® 
by Hoechst Marion Roussel, Inc.) and ormeloxifene (originally manufactured by Torrent 
Pharmaceuticals), which was used as a birth control pill, and is now also prescribed to cure 
uterine bleeding (Blizzard, 2008; Fan et al, 2007; Musa et al, 2007; Sanceau et al, 2007). Pure 
antagonists were also synthesized such as ICI 182,780 (Faslodex® by AstraZeneca), which is 
known as a selective estrogen receptor downregulator; SERD (Abdou et al, 2008).  
In previous research, we showed that bacterial biosensors could detect novel compounds 
and determine their behavior as agonists or antagonists (see structures of discovered 
compounds in Fig. 8 and Table 2) (Hartman et al, 2009; Skretas et al, 2007). Compounds a 
and b were found to bind to ER, and their agonistic and antagonistic effects were verified 
using biosensors. The new findings were confirmed by a fluorescence polarization 
displacement assay using extracts of human ERβ and ERα and fluorescently labeled 
estrogen, as well as by analyzing ERE-dependent luciferase gene activity in human 
embryonic kidney HEK:ERβ and breast cancer MCF-7:D5L cells. The relative binding 
affinities of these compounds, determined by competitive binding assays, showed the ERβ 
selectivity of compound b.  Specifically, the RBA (relative binding affinities of the 
compound to estrogen) of compound a and b for ERα were 0.23±0.03 and 0.59±0.09, and for 
ERβ were 1.94±0.024 and 0.78±0.10, respectively (Skretas et al, 2007). An additional study 
using a luciferase reporter system revealed that compound a is an agonist, but compound b 
is a partial agonist and partial agonist/antagonist when bound to ERα and ERβ, 
respectively.  
 
Compound 
Bacterial Biosensor 
Compound 
Bacterial Biosensor 
Agonist Antagonists Agonist Antagonists 
DES + - Tamoxifen - + 
17-β-
estradiol 
+ - 4-hydroxytamoxifen - + 
Estriol + - Clomiphene - + 
17-α-
estradiol 
+ - Raloxifene - + 
Estrone + - ICI182,780 - + 
Table 2. Bacterial biosensor results obtained for hormones and pharmaceuticals screened 
against human ERβ (Skretas et al, 2007). Concentration of the ligands was 5 µM, with the 
exception of tamoxifen at 2 µM. Antagonists were tested in competitive assays against 500 
nM E2. The (+/-) symbols indicate a positive/negative cell growth outcome. 
The other two compounds, c and d, were originally discovered using a computational 
method known as Shape Signatures (Hartman et al, 2009; Nagarajan et al, 2005; Zauhar et al, 
2003). Shape Signatures was created to rapidly compare chemical databases against known 
active compounds to detect similar bioactivity. This in silico method screens specifically for 
polarity and shape similarities by initially using a ray-tracing algorithm well known in the 
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movie industry to computationally draw shapes of objects in 3D space. The solvent-
accessible surface of each molecule is defined by a Smooth Molecular Surface Triangulator 
algorithm (Zauhar, 1995), and  is essential for defining the volume of a molecule. The shape 
of the molecule, as well as the molecular electrostatic potential computed over the surface of 
the molecule, can be compared across large databases and scored rapidly for the most 
promising compounds. The two molecules c and d (Fig. 8) were derived from a Shape 
Signatures screening against GW7604 and EM652 (see Fig. 3).  
Compounds c and d were determined to bind to the active pocket of ER using Computer-
Aided Drug Design methods, and their behavior was examined using the bacterial 
biosensors and an ERα activation immunoassay (ELISA) containing MCF-7 cell extract 
(Hartman et al, 2009; Skretas et al, 2007). The predicted binding mode of compound c 
overlapped the position of Tamoxifen, which binds through weaker van der Waals 
interactions to the active pocket. Compound d showed possible hydrogen bond formation 
with Glu353.  Overall, compounds c and d were found to be orally bioavailable by Lipinski’s 
Rule of Five, which takes into account solubility, molecular weight, and even the number of 
rotational bonds and hydrogen bond donors and acceptors (Hartman et al, 2009). 
 
(a) 
 
(b) 
(c) (d) 
 
AGONIST 
PARTIAL 
AGONIST/ANTAGONIST 
ANTAGONIST ANTAGONIST 
Fig. 8. The structures of agonists and antagonists discovered and confirmed by commercial 
as well as conventional methods ER (Hartman et al, 2009; Skretas et al, 2007). Names of the 
compounds: (a) 5-[(1E,3E)-4-(4-hydroxyphenyl)-1,3-butadien-1-yl]-1,3-benzenediol; (b) 2 
(1,1-dimethylethyl)-4-[(1E)-2-(4-hydroxyphenyl)ethenyl]-phenol; (c) 3-(2 
aminophenyl)sulfanyl-1-(4-chlorophenyl)-3-phenyl-propan-1-one; (d) 3-(2 
aminophenyl)sulfanyl-3-(4-bromophenyl)-1-phenyl-propan-1-one.  
4. Environmental endocrine disruptors detection 
Synthetic or natural compounds that interfere with hormonal and homeostatic systems are 
known as Endocrine Disruptors (EDs) (Nilsson, 2000). The targets of EDs can be NHRs, non-
hormonal receptors, or numerous biological pathways involved in hormone synthesis, 
metabolism and excretion. Thus, EDs can cause serious disruption of the endocrine system 
by mimicking natural hormones, which may lead to increased or inhibited transcription of 
hormone-regulated genes. Some of these compounds are now associated with various 
cancers, genetic and reproductive diseases, as well as behavioral and developmental 
abnormalities. A few ED-associated disorders seen in humans are also manifest in other 
species, and include uterine leiomyomas, endometriosis, cancers, diabetes and obesity 
(Bryzgalova et al, 2008; Cook et al, 2007; Goksoyr, 2006; Koda et al, 2007; Kuiper et al, 2007; 
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Lee et al, 2007; Lingxia et al, 2007; Maffini et al, 2006; Negri-Cesi et al, 2008; Nilsson, 2000; 
Safe, 2000). EDs comprise a wide range of chemicals, including solvents, pesticides, and 
pharmaceuticals (e.g., DES), and even naturally occurring phytoestrogens in plants 
(McKinlay et al, 2008). Some EDs accumulate in the body, such as uranium from nuclear 
power plants, lead, mercury and cadmium, which travel to the brain and kidney (Raymond-
Whish et al, 2007; Strumylaite et al, 2008; Vahter et al, 2007). Some weakly binding 
compounds, such as BPA, are embedded in plastic bottles used for water and soft drinks 
(Vandenberg et al, 2007). In particular, BPA has been shown to bind to hormone receptors 
across different species. Despite numerous studies on the negative effects of BPA 
(Vandenberg et al, 2009), to this day its impact on the body is still controversial. However, 
the EPA and FDA are now moving to update their disclosures on BPA in response to an 
internal BPA study showing negative effects of exposure on the brain and prostate, as well 
as on the behavior of infants and children (Keri et al, 2007).  
 
Compound Source 
Hexestrol Synthetic, DES derivative 
Genistein Isoflavone, found in plants e.g. soybeans 
Kaempferol Flavonoid, found in plants e.g. tea, apples 
Naringenin Flavonoid, found in plants e.g. grapefruit 
Diphenylnitrosamine (DPN) Synthetic 
BPA Plastics; e.g. bottles, caps 
Apigenin Flavonoid, found in plants e.g. parsley, celery 
Zearalanols Found in plants e.g. fungi (Fusarium) 
Biochanin A Flavonoid, found in plants e.g. peanuts, soy 
Daidzein Isoflavone, naturally found in plants e.g. soybeans 
Phloretin Found in plants e.g. apple leaves 
Naringenin Flavonoid, found in plants e.g. grapefruit 
Table 3. Selected ER agonists detected by bacterial biosensors, including phytogestrogens 
and synthetic estrogen analogs. BPA, DPN and 17-β-estradiol (natural hormone, ER agonist) 
were additionally confirmed to be agonists in the sole and pig ERβ biosensors. BPA and 
Daidzein, despite the fact that they are weak ER agonists, were also detected (Breinholt & 
Larsen, 1998; Collins et al, 1997; Kuiper et al, 1997; Kuiper et al, 1998; Skretas et al, 2007).  
One of the difficulties in determining the impact of EDs on the human body is that although 
a broad range of assays are available, their results are generally not directly comparable. For 
example, the detection limit of a given compound can vary by a factor of 1000 or more 
across several different in-vivo and in-vitro assays (Charles, 2004; Dobbins et al, 2008; 
Kramer, 1998). Measuring the impacts of these compounds on humans is also very difficult, 
especially when evaluating the cumulative impact of EDs over time on the body. Often, 
these assays cannot distinguish between high overall toxicity of EDs and their agonistic and 
antagonistic effects. Non-sigmoidal functions are also observed for some EDs, which exhibit 
U-shaped and inverted-U-shaped dual dose response curves, such as those seen for 
phytoestrogens and neurotransmitters. For example, at low concentrations some 
compounds may act as agonists, but at high concentrations they may behave more like 
www.intechopen.com
Engineered Nuclear Hormone Receptor-Biosensors  
for Environmental Monitoring and Early Drug Discovery 
 
515 
antagonists (Li et al, 2007; Pinto et al, 2008). Additionally, EDs typically exist in the 
environment in mixtures, and therefore there is a need for newly developed HTS assays to 
assess their effects alone and in combination with other compounds (Charles et al, 2007). 
The effect of an ED alone or in a mixture of EDs in different assays may also vary 
(Benachour et al, 2007; Ramamoorthy et al, 1997).  
Since EDs can be accumulated in the body, their half-life could be longer than expected, and 
contact with these chemicals more frequent than expected.  For example, the BPA daily safe 
uptake is 50 µg/kg as determined by the EPA, but it accumulates in fat tissue over time.  
Therefore, additive daily exposure occurs, resulting from a longer than expected half-life in 
the human body (Diamanti-Kandarakis, 2009). Therefore, understanding the impact of these 
chemicals on the endocrine system and human health is challenging, especially for weakly 
binding EDs like BPA.  
The bacterial biosensors can easily differentiate between bacterial toxicity and endocrine 
activity. Examples of compounds that bind to ERs, and their sources, are shown in Table 3 
Some of them are naturally occurring chemicals found in plants, but others are synthetic. In 
each case, these compounds mimic estrogen, but their structure is not typically steroid-like 
(see examples of DES, BPA in Fig. 3). In some cases, the compounds could be beneficial (e.g., 
chemopreventive properties of Apigenin; antidepressant properties of Kaempferol) as well 
as harmful or epigenetic (BPA, DES and Hexestrol).   
4.1 Screening of home products for estrogenic activity 
The intein-based biosensors are capable of detecting small amounts of estrogenic 
compounds in consumer products such as perfumes, pills and plant extracts. A study using 
the bacterial biosensors showed that chemicals such as benzophenone-2 (see Fig. 3), which is 
a UV absorber used in plastic food containers and cosmetics, can be detected by this 
method. Benzophenone-2 (BP-2) has an agonistic effect on the human ER, and several 
publications suggest estrogenic effects on fish (juvenile fathead minnows) as well rats (Kunz 
et al, 2006; Schlecht et al, 2008; Seidlova-Wuttke et al, 2004). In other studies, BP-2 was 
shown to have an agonistic effect on fish (rainbow trout) and human ERs, and was found to 
be selective for human ERβ in an in vitro bioassay (Molina-Molina et al, 2008). BP-2 was also 
tested in pregnant mice to determine its impact on fetuses, where it was found that BP-2 
may be a cause of hypospadia which is an abnormality in the reproductive organs of male 
fetuses (Hsieh et al, 2007). Additionally, BP-2 suppresses T4 (thyroid hormone), but not T3, 
and has estrogenic activity in rats (Seidlova-Wuttke et al, 2005). The results obtained by the 
bacterial biosensors also suggest an agonistic effect of BP-2 on the human ERβ. Several 
perfumes were tested, including Notes by Celine Dion, Amber Romance by Victoria’s Secret, 
Roma by Laura Biagiotti and Haiku by Avon. All of the tested perfumes that contain BP-2 as 
an ingredient had an agonistic effect on ERβ biosensor, but no effect on the TRβ biosensor. 
Tests of several natural menopause-relief pills showed a weak positive effect in many cases 
as well, which included Black Cohosh and Dong Quai Capsules by Nature’s Way, and Black 
Cohosh and Dong Quai Capsules by Gaia Herbs. Notably, essential oils (e.g., Lavender Oil 
by Plantlife) and soaps were screened but were toxic to the bacterial cells (Gawrys et al, 
2009).   
4.2 Testing endocrine disruptors across species 
The human NHR LBDs of the biosensors can be easily exchanged for animal LBDs and the 
effects due to the same set of ligands can be compared. The sequences of ERβ for Sus scrofa 
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and Solea solea were inserted in place of human ERβ in the pMIT::ERβ*, and the potencies of 
DES, BPA, DPN, Daidzein and E2 were compared. The potencies across species showed that 
DES and E2 have the strongest effect on all of fish, pig and human biosensors. DES was 
almost twice as effective on pig than on fish or human. The weakest effect was noticed for 
BPA in the order human>fish>pig. The half maximal effective concentrations (EC50s) were 
compared to determine relative pseudotransactivation (RPTA, see Equation (1)). The EC50 
values and the standard deviations of data obtained in triplicate can be presented as 
sigmoidal plots of OD vs. log of test compound concentration. The calculations were based 
on nonlinear regression with variable Hill slope (GraphPad Prism 5.01; GraphPad Software, 
La Jolla, CA, USA). 
 RPTA=
2E
50
ligand
50
EC
EC
x100%  (1) 
However, the RPTA values for DPN were quite close to E2 for human (~80%), but showed it 
to be less potent for pig (33%) and fish (12%). An even smaller relative effect was seen for 
Daidzein, commonly found in soybeans, on human ERβ (4%) ≈ pig (4%) > fish (0.9%). 
Similarly, BPA had very little effect on fish (5.6%) > human (0.9%) > pig (0.23%). The two-
tailed p values with 95% confidence interval verified significant correlation between EC50 
values of tested compounds on human and porcine ERβs. There was no correlation of those 
ERs with sole ERβ. To further examine the quality of the assay, the Z’ factor for each 
measurement was calculated, which is an indication of signal to noise in a measurement (see 
Equation (2); (Zhang et al, 1999)). In both cases the data were sufficient to distinguish ER 
agonists across species in HTS set up, where Z’ factor above zero is needed to robustly 
determine whether a given ligand is a potential EDC. In general, all of the tests produced 
very good Z’ factors, ranging from the strong agonist E2 (Z’ factor of 0.4-0.6 across the three 
tested species), to the weaker agonist BPA (Z’ factor of 0.15-0.32) (Gierach et al, 2011).  
 Z’=1- max min
max min
3x(SD SD )
Mean Mean
+
−
 (2) 
The data obtained here were also compared to the literature. The trends of recorded effects 
of ligands on human and pig ERs were similar (DES>>E2>Daidzein>BPA). Weaker binders 
like Daidzein and BPA were also tested previously in a yeast transcriptional assay, and the 
values obtained from these studies closely correlated with our findings (2.5x10-7 M (yeast 
assay) vs. 1.7x10-6 M (bacterial assay) and 1.45x10-7 M (yeast assay) vs. 3.6x10-7 M (bacterial 
assay), respectively; (Chu et al, 2009)). The performance of the Solea solea biosensor was 
more difficult to ascertain, due to a relative lack of available data compared to carp 
(Cyprinus carpio) and rainbow trout (Oncorhynchus mykiss) (Matthews et al, 2000; Matthews 
et al, 2001; Petit et al, 1995). In general, however, in vivo tests in other piscine species were 
less sensitive for weak binders, such as BPA.  In this case, a hepatocyte vitellogenin secretion 
test at up to 100 µM concentration of BPA showed limited response (Smeets et al, 1999). Our 
studies were able to determine the binding effect of BPA in sole at lower concentrations 
(0.10 to 9.85 µM). In other previous assays where piscine ERs were tested, trends in the 
strength of binding were similar to those observed for Daidzein and DPN in the bacterial 
biosensors. The alternate assays included a displacement assay using a trout ER nuclear 
extract, or the previously mentioned hepatocyte vitellogenin secretion assay. A correlation 
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between all of these assays was seen for strong binders, such as E2, which closely 
corresponded with in vivo studies: 50-150 nM (vitellogenin assay) (Smeets et al, 1999) vs. 21-
153 nM (bacterial biosensor assay).  
 
Method Detection Bacterial Host Reference 
Heavy metals 
Green fluorescent 
protein (GFP)-based 
bacterial biosensors 
Cd(II), Pb(II), and Sb(III) in 
sediments and soils 
Escherichia coli (Liao et al, 2006) 
GFP bacterial 
biosensor 
As Escherichia coli (Tani et al, 2009) 
Bioluminescent 
bacterial biosensor 
Cu, Zn, Cd, Co, Ni, Pb 
Alcaligenes 
eutrophus 
(Collard et al, 1994; 
Diels et al, 1999) 
Fibre-optic 
luminescent bacterial 
biosensors 
Hg and As in soils and sediments Escherichia coli (Ivask et al, 2007) 
Antibiotics 
Colorimetric bacterial 
biosensor dipstick-
based technology 
Tetracycline, streptogramin and 
macrolide in food 
Escherichia coli (Link et al, 2007) 
Luminescent bacterial 
biosensor 
Tetracyclines in poultry muscle Escherichia coli (Pikkemaat et al, 2010) 
Hormones, Pharmaceuticals, Endocrine Disruptors 
Cell growth based TS-
deficient NHR 
bacterial biosensors 
Wide variety of compounds e.g. 
estradiol, T3, triac, tamoxifen, 
GC-1, diethylstilbestrol, KB-141, 
daidzein, DPN and genistein 
Escherichia coli
(Gawrys et al, 2009; 
Hartman et al, 2009; 
Skretas et al, 2007; 
Skretas & Wood, 2005a, 
2005b, 2005c ) 
Electrochemical 
bacterial biosensors 
Aromatic hydrocarbons and 
heavy metals 
Escherichia coli (Paitan et al, 2003) 
Fluorescent and 
luminescent toluene 
bacterial biosensors 
Environmental pollution with 
petroleum products e.g. benzene, 
toluene, ethylbenzene, and 
xylenes
Escherichia coli (Li et al, 2008) 
Bioluminescent 
naphthalene biosensor
Naphthalene 
Pseudomonas 
putida 
(Werlen et al, 2004) 
DNA 
Bioluminescent 
bacterial biosensor for 
DNA damage, 
alkylation and 
mutagenicity 
recognition 
Genotoxicants included: 
endocrine disrupting chemicals, 
phenolitics and compounds 
causing oxidative stress (e.g. 
H2O2, CdCl) 
Escherichia coli (Ahn et al, 2009) 
Microgravity and 
space radiation 
bacterial biosensors 
Analysis of the level of radiation 
exposure on human body by 
bacterial detection 
Salmonella 
typhimurium 
(Rabbow et al, 2003) 
Stress-responsive 
bacterial biosensors
DNA damage by oxidative and 
genotoxic conditions
Escherichia coli (Mitchell & Gu, 2004) 
Table 4. The review of bacterial biosensors usage.   
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5. Brief overview of other bacterial biosensors 
The intein-NHR bacterial biosensors are useful for ED screening and drug discovery, and 
exhibit many advantages over conventional assays. These advantages are also observed in 
other bacterial biosensor systems, which have been extended into wide range of 
applications.  These include testing for antibiotics in food, as well as detecting DNA damage 
by chemicals and even space radiation. Several examples of other bacterial biosensors are 
included in Table 4.  
6. Conclusions 
The bacterial biosensors presented here are an excellent tool for screening EDs, 
pharmaceuticals, hormones or mixtures of compounds for their agonism or antagonism 
against human NHRs as well as NHRs of other species. These biosensors meet the need for a 
method to rapidly compare the effects of NHR ligands across different species, and to 
estimate the potential danger of chemicals in the environment. These bacterial biosensors 
can be also used to rapidly and cheaply test large amounts of the unknown chemicals for 
possible future uses as lead compounds in pharmaceutical research, including compounds 
with receptor sub-type selectivity. The simplicity of the assay and very low cost are 
attractive key features of this method.  
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